These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24980948)

  • 1. Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).
    Huck JJ; Zhang M; Mettetal J; Chakravarty A; Venkatakrishnan K; Zhou X; Kleinfield R; Hyer ML; Kannan K; Shinde V; Dorner A; Manfredi MG; Shyu WC; Ecsedy JA
    Mol Cancer Ther; 2014 Sep; 13(9):2170-83. PubMed ID: 24980948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
    Graff JN; Higano CS; Hahn NM; Taylor MH; Zhang B; Zhou X; Venkatakrishnan K; Leonard EJ; Sarantopoulos J
    Cancer; 2016 Aug; 122(16):2524-33. PubMed ID: 27192055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
    Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
    Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
    Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Kelly KR; Shea TC; Goy A; Berdeja JG; Reeder CB; McDonagh KT; Zhou X; Danaee H; Liu H; Ecsedy JA; Niu H; Benaim E; Iyer SP
    Invest New Drugs; 2014 Jun; 32(3):489-99. PubMed ID: 24352795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.
    Venkatakrishnan K; Zhou X; Ecsedy J; Mould DR; Liu H; Danaee H; Fingert H; Kleinfield R; Milton A
    J Clin Pharmacol; 2015 Mar; 55(3):336-47. PubMed ID: 25302940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
    Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
    Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
    Niu H; Shin H; Gao F; Zhang J; Bahamon B; Danaee H; Melichar B; Schilder RJ; Coleman RL; Falchook G; Adenis A; Behbakht K; DeMichele A; Dees EC; Perez K; Matulonis U; Sawrycki P; Huebner D; Ecsedy J
    EBioMedicine; 2017 Nov; 25():50-57. PubMed ID: 29122619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
    Falchook GS; Zhou X; Venkatakrishnan K; Kurzrock R; Mahalingam D; Goldman JW; Jung J; Ullmann CD; Milch C; Rosen LS; Sarantopoulos J
    Drugs R D; 2016 Mar; 16(1):45-52. PubMed ID: 26689566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
    Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
    Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
    Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
    Cervantes A; Elez E; Roda D; Ecsedy J; Macarulla T; Venkatakrishnan K; Roselló S; Andreu J; Jung J; Sanchis-Garcia JM; Piera A; Blasco I; Maños L; Pérez-Fidalgo JA; Fingert H; Baselga J; Tabernero J
    Clin Cancer Res; 2012 Sep; 18(17):4764-74. PubMed ID: 22753585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.
    Dees EC; Cohen RB; von Mehren M; Stinchcombe TE; Liu H; Venkatakrishnan K; Manfredi M; Fingert H; Burris HA; Infante JR
    Clin Cancer Res; 2012 Sep; 18(17):4775-84. PubMed ID: 22767670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
    Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
    Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
    Falchook G; Kurzrock R; Gouw L; Hong D; McGregor KA; Zhou X; Shi H; Fingert H; Sharma S
    Invest New Drugs; 2014 Dec; 32(6):1181-7. PubMed ID: 24879333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
    Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
    Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
    Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
    Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
    Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
    Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
    Davis SL; Ionkina AA; Bagby SM; Orth JD; Gittleman B; Marcus JM; Lam ET; Corr BR; O'Bryant CL; Glode AE; Tan AC; Kim J; Tentler JJ; Capasso A; Lopez KL; Gustafson DL; Messersmith WA; Leong S; Eckhardt SG; Pitts TM; Diamond JR
    Clin Cancer Res; 2020 Sep; 26(17):4633-4642. PubMed ID: 32414750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.